An optical backup apparatus is provided and includes an optical storage device, an interface module to connect with at least one type of external storage medium, and a control unit to back up data from the external storage medium to the optical storage device in response to an external remote control operation.

A mechanism is provided in a storage device for performing a write operation. The mechanism configures a write buffer memory with a plurality of write buffer portions. Each write buffer portion is dedicated to a predetermined block size category within a plurality of block size categories. For each write operation from an initiator, the mechanism determines a block size category of the write operation. The mechanism performs each write operation by writing to a write buffer portion within the plurality of write buffer portions corresponding to the block size category of the write operation.

Various systems and methods are described for configuring a logical data storage container. In one embodiment, an instruction to perform an operation to modify an attribute of the logical data storage container that is an abstraction of a plurality of pertinent storage containers is received. A translated instruction to perform a sub-operation associated with the operation is transmitted to each of a number of the plurality of pertinent storage containers. A level of success of the performing of the operation on the logical data storage container is detected based on a comparison of a threshold value to a level of success of the performing of the sub-operation on each of the number of the plurality of pertinent storage containers. A report of the detected level of success is communicated.

A dynamically expandable and contractible fault-tolerant storage system employs a virtual hot spare that is created from unused storage capacity across a plurality of storage devices. This unused storage capacity is available if and when a storage device fails for storage of data recovered from the remaining storage device(s). On an ongoing basis, the storage system may determine the amount of unused storage capacity that would be required for the virtual hot spare (e.g., based on the number of storage devices, the capacities of the various storage devices, the amount of data stored, and the manner in which the data is stored) and generate a signal if additional storage capacity is needed for a virtual hot spare.

The invention discloses a deep-ultraviolet chemically-amplified positive photoresist. The deep-ultraviolet chemically-amplified positive photoresist according to one embodiment of the invention includes a cyclopentenyl pimaric acid, a divinyl ether, a photoacid generator and an organic solvent. The deep-ultraviolet chemically-amplified positive photoresist according to the invention has a good sensitivity and a good transparency.

The polycyclic organic compounds which are substantially transparent for an electromagnetic radiation in the visible spectral range, an anisotropic optical film comprising at least one polycyclic organic compound and a method of producing thereof are disclosed. The polycyclic organic compounds have a general formula (I) wherein A and B are acid groups, n is the number of phenyl rings in the range from 3 to 10; m is 0, 1, 2 or 3; l is 1, 2, or 3, p is 1, 2, 3, 4, 5 or 6, C is a counterion from a list comprising H+, NH+4, Na+, K+, Li+, Cs+, Ca2+, Mg2+, Sr2+, La3+, Zn2+, Zr4+, Ce3+, Y3+, Yb3+, Gd3+, and any combination thereof; k is the number of counterions necessary for compensation of the negative electric charge equal to (−p).

Medical devices comprising an anti-connexin agent suitable for introduction into a subject.

The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.

A recombinant micro-organism producing resveratrol by a pathway in which phenylalanine ammonia lyase (PAL) produces trans-cinnamic acid from phenylalanine, cinnamate 4-hydroxylase (C4H) produces 4-coumaric acid from said trans-cinnamic acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA, or in which L-phenylalanine- or tyrosine-ammonia lyase (PAL/TAL) produces 4-coumaric acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA. The micro-organism may be a yeast, fungus or bacterium including Saccharomyces cerevisiae, E. coli, Lactococcus lactis, Aspergillus niger, or Aspergillus oryzae.

An optical disc drive (ODD) includes a radio-frequency identification (RFID) reader. The reader includes a circuit and a coil antenna which has a rotational symmetry with respect to a rotation axis of a motor, shaft and turntable of the ODD. The coil antenna can be secured to a wall of a housing of the ODD or around the motor and/or shaft. The reader can read an RFID tag on an optical disc. The RFID tag includes a circuit and a coil antenna which has a rotational symmetry with respect to the disc. As a result, the RFID tag can be read while the disc is rotating. A magnetic insulating material such as a ferrite polymer composite film is used to magnetically insulate the coil antenna. An authentication code can be read from the RFID tag to control access to content of the optical disc.

A method uses a firmware interface setup program for a selected compute node (“node”) to cause a firmware interface to enable a trusted platform module (TPM) on the selected node to receive a physical presence (PP) signal. The selected node is selected from a plurality of nodes within a multi-node chassis, wherein each node includes a firmware interface and a TPM. A device within the multi-node chassis is manually actuated to transmit a PP signal to each of the plurality of nodes, such that each node receives the PP signal. The PP signal is asserted to the TPM of the selected node in response to both enabling the TPM of the selected node to be able to receive the PP signal and receiving the PP signal. Still further, the method allows modification of a security setting of the selected node in response to the TPM receiving the PP signal.

Systems and methods are disclosed for evaluating cardiovascular treatment options for a patient. One method includes creating a three-dimensional model representing a portion of the patient's heart based on patient-specific data regarding a geometry of the patient's heart or vasculature; and for a plurality of treatment options for the patient's heart or vasculature, modifying at least one of the three-dimensional model and a reduced order model based on the three-dimensional model. The method also includes determining, for each of the plurality of treatment options, a value of a blood flow characteristic, by solving at least one of the modified three-dimensional model and the modified reduced order model; and identifying one of the plurality of treatment options that solves a function of at least one of: the determined blood flow characteristics of the patient's heart or vasculature, and one or more costs of each of the plurality of treatment options.

A system for facilitating remote medical diagnosis and consultation of heart disease for a patient, the system comprising: a diagnostic device for performing Electrocardiography on the patient, a network device in communication with the diagnostic device via wired or wireless communication links, a software program pre-installed in the network device, a server located remotely, wherein during operation, the patient activates the diagnostic device which will perform Electrocardiography on the patient, the diagnostic device receives diagnostic data and transmits the diagnostic data to the network device, the software program transmit the diagnostic data to over a network to a server which a physician have access to, and based on the diagnostic data gathered by the server and some additional medical data, the physician can review the patient's health condition and offer an appropriate feedback and diagnosis for the patient.

An apparatus and method for determining a signal quality of an input signal representing a repetitious phenomena derived from at least one sensor connected to a patient is provided. A detector receives the input signal and determines data representing the repetitious phenomena from the input signal for use in determining at least one patient parameter. A measurement processor is electrically coupled to the detector that determines a first signal quality value by identifying at least one feature of the repetitious phenomena data and compares the at least one feature of a first set of the determined repetitious phenomena data with a second set of the determined repetitious phenomena data to determine a feature variability value and using the feature variability value to determine a stability value representative of the quality of the input signal.

A method and system are provided for determining a condition of a selected region of epithelial and stromal tissue in the human breast. A plurality of measuring electrodes are used to measure the tissue and transepithelial electropotential of breast tissue. Surface electropotential and impedance are also measured at one or more locations. An agent may be introduced into the region of tissue to enhance electrophysiological characteristics. The condition of the tissue is determined based on the electropotential and impedance profile at different depths of the epithelium, stroma, tissue, or organ, together with an estimate of the functional changes in the epithelium due to altered ion transport and electrophysiological properties of the tissue. Devices for practicing the disclosed methods are also provided.

The present disclosure relates to a system for use in surgical procedures. The system includes an endoscope; an imaging device coupled to the endoscope; an imaging processor coupled to the imaging device; and at least one management system coupled to the imaging processor, wherein a function of the management system is automatically adjusted upon receipt of a communication from the imaging processor. A method of adjusting an image of a surgical site during a surgical procedure is also disclosed.

A chemically amplified resist composition comprising a base polymer and an amine quencher in the form of a β-alanine, γ-aminobutyric acid, 5-aminovaleric acid, 6-aminocaproic acid, 7-aminoheptanoic acid. 8-aminooctanoic acid or 9-aminononanoic acid derivative having an unsubstituted carboxyl group has a high contrast of alkaline dissolution in rate before and after exposure and forms a pattern of good profile at a high resolution, minimal roughness and wide DOF.

The subject of the present invention are novel esters of (acyloxymethyl)acrylamide, a pharmaceutical composition containing them and their use in the production of drugs for the prophylaxis or treatment of oncogenic diseases and diseases connected with increased cell proliferation.

A phenyl alkyl carbamate derivative compound and a pharmaceutical composition containing the compound are provided. More specifically, the phenyl alkyl carbamate derivative compound and a pharmaceutically acceptable salt thereof, a composition for muscle relaxation containing the phenyl alkyl carbamate derivative compounds and/or pharmaceutically acceptable salt thereof as an active ingredient, and a method of muscle relaxation comprising administering a pharmaceutically effective amount of the phenyl alkyl carbamate derivative compound and/or a pharmaceutically acceptable salt thereof to a subject in need of to a subject in need of, are provided.

An object of the present invention is to improve the stability of an ethylenically unsaturated compound having an isocyanate group in the molecule by preventing a polymerization of the ethylenically unsaturated compound. The present invention relates to a stabilizing composition for an isocyanate group-containing ethylenically unsaturated compound, comprising: an isocyanate group-containing ethylenically unsaturated compound (A) which comprises one or more isocyanate groups and one or more ethylenically unsaturated groups in the molecule; and a stabilizing agent (B) which is a compound in which at least one of the ethylenically unsaturated groups in the compound (A) is replaced with an alkyl group which may have a substituent.

Provided is a compound which has strong and sustaining intraocular pressure lowering action and, further, has no fear of side effect on eyes. Since a compound represented by the formula (I): wherein definition of each group is as described in the specification, or a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering action and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and/or treating glaucoma etc.

The present invention relates to new salts of 6-(propyl-(2-thiophen-2-ylethyl)amino)tetralin-1-ol(rotigotine), their use as a medicament, for example for the treatment of CNS disorders like Parkinson Disease, RLS, fibromyalgia and/or depression, in particular through electromotive administration. The present invention relates to pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of rotigotine to at least one target tissue. The formulations are further characterized by good to excellent solubility of the salts in aqueous solutions.

A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.

A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents; and the amount of viscosity modifying agents can optionally be reduced by at least an amount by weight that would have increased the viscosity of the carrier without the tetracycline antibiotic by at least 30%; wherein the tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down; wherein when packaged in an aerosol container to which is added a liquefied or compressed gas propellant the composition affords upon release from the container a breakable foam of at least good quality that breaks easily upon application of shear force.

A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity of the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.

The invention relates to a solid pharmaceutical composition comprising solid amorphous fulvestrant, said composition being formulated in combination with a solubilizing composition. The invention also relates to a method for preparing said composition and a kit including the composition.

The present invention comprises formulations comprising at least one pesticide and at least one co-polymer comprising a) 1-vinyl-2-pyrrolidinone as comonomer a); and b) 60-99 wt % at least one comonomer b) chosen from the group of laurylacrylate and vinyl ester of neodecanoic acid in polymerized form, methods of combating harmful insects and/or phytopathogenic fungi, a method of controlling undesired vegetation and methods of improving the health of plants based on the afore-mentioned formulations.

The present invention is directed towards microcapsules, uses and methods of microencapsulation with improved properties regarding agglomeration, bleeding and control of the reaction. The invention is especially suitable for chemical compounds with at least one carboxamide group, preferably for microencapsulation of those compounds wherein the carbonyl group is attached to a nitrogen atom or nitrogenated heterocycle and wherein the microencapsulation reaction may be too vigorous. The microcapsules are characterized by a mixed glycoluril-polyurea polymer wall, wherein the polyurea groups come from a urea-formaldehyde resin and not from isocyanate monomers or prepolymers. The process of making such microcapsules a dispersant in the oil phase of the type of block copolymer of vinylpyrrolidone/vinylalkene and/or vinylpyrrolidone/vinyl acetate and the microencapsulation reaction may be carried out without the presence of any polyamine/polyol acting as a catalyst.

The present invention relates to an pesticidal composition comprising an effective amount of a sulphur; an effective amount of at least one insecticide selected from the group consisting of cartap fipronil, pirimicarb, buprofezine, thiachloprid, acetamiprid, clothianidin, diafenthiuron, novaluron, flubendiamide, spirotetramat, thiamethoxam, imidacloprid or salts thereof, and at least one agrochemically acceptable excipient.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.

Disclosed herein are mesocapsules that include agriculturally active ingredients. These mesocapsules are comprised of a polyurea shell and include hydrophilic groups on their surfaces and have a volume-average diameter of about 500 nm or less and some of them have a volume-average diameter on the order of about 300 nm or less. These mesocapsules are suited for delivering active ingredients that are not very soluble in water. Methods for making these mesocapsules include interfacial polycondensation reactions carried out in the presence of surfactants and other methods in which all or most of the surfactant is replaced by adding amino acids to the aqueous phase of the interfacial reaction mixture before forming the final emulsion.

Bioactive agrichemical concentrates and compositions having improved bioactivity comprising combinations of acid solutions and conventional bioactive agrichemical actives or formulations.

Methods, systems, and computer readable media for monitored application of mechanical force to samples using acoustic energy and mechanical parameter value extraction using mechanical response models can be used for determining mechanical property parameters of a sample. An exemplary method includes applying acoustic energy to a sample to apply a mechanical force to the sample, measuring a response by the sample during the application of the acoustic energy, measuring a recovery response of the sample following cessation of the application of the acoustic energy, and determining a value for at least one additional mechanical property parameter of the sample based on the response measured during application of the acoustic energy and the recovery response measured following cessation of the application of acoustic energy.

A method for providing a biological logic gate comprising the following steps: subjecting a bistable autoregulatory gene network (GRN) to a noisy background; identifying adjustable parameters of the GRN; using logical stochastic resonance to determine values of the GRN parameters which result in the GRN performing different logic gate functions; and setting the parameter values of the GRN such that the GRN performs a first logic gate function.

The methods described herein enable the evaluation of compounds on subjects to assess their therapeutic efficacy or toxic effects. The target of analysis is the underlying biochemical process or processes (i.e., metabolic process) thought to be involved in disease pathogenesis. Molecular flux rates within the one or more biochemical processes serve as biomarkers and are quantitated and compared with the molecular flux rates (i.e., biomarker) from control subjects (i.e., subjects not exposed to the compounds). Any change in the biomarker in the subject relative to the biomarker in the control subject provides information to evaluate therapeutic efficacy of an administered drug or a toxic effect and to develop the compound further if desired. In one aspect of the invention, stable isotope-labeled substrate molecules are administered to a subject and the label is incorporated into targeted molecules in a manner that reveals molecular flux rates through metabolic pathways of interest.

Provided is a pressure-sensitive adhesive for polarizing plates which can adhere a polarizing plate on a liquid crystal cell with good adhesion durability and has the characteristic that a liquid crystal display device obtained therefrom is less liable to cause light leakage even under the environment of high temperature and high humidity and which makes it possible remove the polarizing plate. The pressure-sensitive adhesive for polarizing plates is prepared by irradiating a pressure-sensitive adhesive material comprising (A) an acrylic base polymer having a weight average molecular weight of 1,000,000 or more comprising a monomer having a hydroxyl group in a monomer composition ratio of 10 mass % or less, (B) an acrylic base polymer having a weight average molecular weight of 1,000,000 or more comprising a monomer having a carboxyl group in a monomer composition ratio of 10 mass % or less and (C) an active energy beam-curable compound with an active energy beam, wherein a mass ratio of the component (A) to the component (B) is 100:1 to 100:50, and a storage elastic modulus (G') at 23° C. is 0.3 MPa or more.

Methods are disclosed for synthesizing nanocomposite materials including ferromagnetic nanoparticles with polymer shells formed by controlled surface polymerization. The polymer shells prevent the nanoparticles from forming agglomerates and preserve the size dispersion of the nanoparticles. The nanocomposite particles can be further networked in suitable polymer hosts to tune mechanical, optical, and thermal properties of the final composite polymer system. An exemplary method includes forming a polymer shell on a nanoparticle surface by adding molecules of at least one monomer and optionally of at least one tethering agent to the nanoparticles, and then exposing to electromagnetic radiation at a wavelength selected to induce bonding between the nanoparticle and the molecules, to form a polymer shell bonded to the particle and optionally to a polymer host matrix. The nanocomposite materials can be used in various magneto-optic applications.

A procedure for improved temperature control in controlled radical polymerization processes is disclosed. The procedure is directed at controlling the concentration of the persistent radical in ATRP and NMP polymerizations procedures and the concentration of radicals in a RAFT polymerization process by feeding a reducing agent or radical precursor continuously or intermittently to the reaction medium through one of more ports.

The present invention provides an acrylic resin composition containing a polycrystal of colloidal particles of silicon oxide in an acrylic resin that is formed by curing an acrylic monomer liquid at room temperature and/or an acrylic oligomer liquid at room temperature, wherein a mean distance between the colloidal particles in the polycrystal is 140 to 330 nm. The size of the single crystal that constitutes the polycrystal can be controlled by adjusting the content of silicon oxide and/or the additive amount of impurities. An architectural material, a fashion accessory, and an optical material are provided that are formed by using the acrylic resin composition.

A separator includes a centrifugal drum having a vertical axis of rotation and a feed line for material to be centrifuged. A drive spindle for the centrifugal drum is rotatably mounted on a housing via a bearing, the housing being supported elastically on a machine frame. A drive device includes a motor housing and an electric motor having a stator and an armature which is aligned with the drive spindle. The drive device and the motor housing move with the drive spindle as co-vibrating units during an operation of the separator. The drive device is connected to the machine frame below the bearing at a lower axial end of the bearing via one or more joint elements.

A gripper unit for handling a vessel for receiving biological material is proposed, inter alia. The vessel has a lid which can assume an open position and a closed position. The gripper unit comprises a gripper for gripping and releasing the vessel, and a lid holder, for holding a lid in a defined position in relation to the vessel. The defined position is an open position of the lid.

A lipoaspirate collection device to aid in the collection and processing of human tissue and fluid obtained during liposuction for use in point-of-care cell therapy. The collection device includes a collection body and a collection cap. The collection cap may have a fluid port, a lipoaspirate port, a vacuum port, and a relief valve. Within the central cavity of the collection device, a cone shaped may be positioned such that the apex of the cone is positioned underneath the lipoaspirate inlet through which the lipoaspirate fluid and tissue are introduced.

The invention refers to a centrifuge for separating whole blood into its blood components and a method for extracting a highly enriched thrombocyte concentrate out of whole blood. For this purpose, the centrifuge comprises a closed loop and/or open-loop control unit as well as a drive unit coupled to the closed loop and/or open-loop control unit, a rotor (12) having at least two container receptacles (14a, 14b; 16a, 16) for removably holding containers (18, 20, 22, 24) being in fluid communication with each other, at least one sensor arranged between the container receptacles (14a, 14b; 16a, 16b) and coupled with the closed loop and/or open-loop control unit for detecting a separation layer. Herein, a motor/gear unit (30a, 30b, 32a, 32b) coupled to the closed loop and/or open-loop control unit is associated with each of the container receptacles (14a, 14b; 16a, 16b). Each of the motor/gear units is in operational contact through means (34) with each of the containers (18, 20, 22, 24) supported in the respective container receptacle (14a, 14b; 16a, 16b) such that a transfer and back-transfer of blood components between the containers (18, 20, 22, 24) is initiated.

A vertical centrifugal separator includes a casing, a bowl that is rotatably housed in the casing and provided to separate a solution to be processed which is supplied to an interior of the bowl into a liquid and a solid by an action of centrifugal force and discharge the liquid and the solid, and a discharge assembly that is rotatably housed in the bowl and provided to discharge the solid in the bowl. The bowl and the discharge assembly each have an engagement portion that is engaged or disengaged when the bowl and the discharge assembly are moved relative to each other in an axial direction and a position adjustment mechanism for adjusting a phase between the discharge assembly and the bowl relative to a rotation axis, for example, at a single relative position.

This invention is related to a pharmaceutical combination that contains a Casein kinase 2 (CK2) peptide inhibitor (termed P15) along with the standard chemotherapeutic drugs used in cancer treatment and which are administered together, separated or sequentially. The chemotherapeutic drugs include cisplatin, taxol, alkaloids from Vinca, 5-fluorouracil, doxorubicin, cyclophosphamide, etoposide, mitomicin C, imatinib, iressa and velcade (vortezomib). The synergism between the P15 peptide and the anticancer drugs achieves an efficient concentration of each cytostatic drug in the combination which is from 10- to 100-fold lower than that for each cytostatic drug alone. The pharmaceutical combination described in this invention exhibits lower toxicity compared to that reported by the anticancer therapeutics and therefore, it represents a crucial advantage for its use in cancer therapy. Furthermore, the sequential administration of this pharmaceutical combination through the pretreatment with the P15 peptide leads to the chemo sensibilization of refractory tumors to the anticancer therapeutics.

A system for intelligent monitoring and management of an electrical system is disclosed. The system includes a data acquisition component, a power analytics server and a client terminal. The data acquisition component acquires real-time data output from the electrical system. The power analytics server is comprised of a real-time energy pricing engine, virtual system modeling engine, an analytics engine, a machine learning engine and a schematic user interface creator engine. The real-time energy pricing engine generates real-time utility power pricing data. The virtual system modeling engine generates predicted data output for the electrical system. The analytics engine monitors real-time data output and predicted data output of the electrical system. The machine learning engine stores acid processes patterns observed from the real-time data output and the predicted data output to forecast an aspect of the electrical system.

Method and system are disclosed for statistical circuit simulation. In one embodiment, a computer implemented method for statistical circuit simulation includes providing descriptions of a circuit for simulation, wherein the descriptions include variations of statistical parameters of the circuit, partitioning the circuit into groups of netlists according to variations of statistical parameters of the circuit, simulating the groups of netlists using a plurality of processors in parallel to generate a plurality of output data files, and storing the plurality of output data files in a memory. The method of partitioning the circuit into groups of netlists includes forming the groups of netlists to be simulated in a single instruction multiple data environment, and forming the groups of netlists according to proximity of variations of statistical parameters of the circuit.

Techniques are described for implementing one or more logical routers within a single physical routing device. These logical routers, as referred to herein, are logically isolated in the sense that they achieve operational and organizational isolation within the routing device without requiring the use of additional or redundant hardware, e.g., additional hardware-based routing controllers. The routing device may, for example, include a computing platform, and a plurality of software process executing within the computing platform, wherein the software processes operate as logical routers. The routing device may include a forwarding component shared by the logical routers to forward network packets received from a network in accordance with the forwarding tables.

In a method for simulating temperature and electrical characteristics within an circuit, a temperature of at least one volume within the circuit as a function of a resistance within the at least one volume is repeatedly calculated and the resistance as a function of the temperature is repeatedly calculated until the temperature is within a predetermined tolerance of a previous temperature result and until the resistance is within a predetermined tolerance of a previous resistance result. Once the temperature is within a predetermined tolerance of the previous temperature result and the resistance is within a predetermined tolerance of the previous resistance, then an output indicative of the temperature is generated.

A device for the collection and processing of information relating to the exposure of one or more persons to one or more products of chemical or biological origin has: at least one coded sensor for automatic or semi-automatic identification of a person likely to be exposed to at least one product,at least one coded sensor for the collection of information relating to the handling of at least one product by the person likely to be exposed to the product,at least one sensor for validating the information collected by the identification and collection sensors,at least one module for reading at least one coded sensor, anda module for processing information collected by the sensors.